Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the peptidoglycan precursor lipid II is a critical structural motif in the assembly of the Gram-positive bacterial cell wall (Source: Nature Reviews Microbiology, 2008). Lipid II serves as the essential carrier that transports peptidoglycan subunits across the cytoplasmic membrane to the site of cell wall synthesis. The D-Ala-D-Ala dipeptide at the end of the pentapeptide chain is the specific substrate recognized by transpeptidase enzymes, also known as penicillin-binding proteins, which catalyze the cross-linking of the peptidoglycan layer. This terminus is the primary molecular target for glycopeptide antibiotics, such as vancomycin and teicoplanin (Source: StatPearls, 2023). By binding with high affinity to this dipeptide via five hydrogen bonds, these drugs sterically hinder the enzymatic reactions required for cell wall polymerization, ultimately leading to bacterial cell death. Resistance to these antibiotics often involves the modification of this target to D-alanyl-D-lactate or D-alanyl-D-serine, which significantly reduces drug binding affinity (Source: Clinical Microbiology Reviews, 2019). This target is unique to bacteria, providing a high degree of selective toxicity for therapeutic intervention.
Glycopeptide antibiotics bind to the D-alanyl-D-alanine terminus of the peptidoglycan precursor lipid II via five hydrogen bonds. This binding sterically inhibits the transglycosylation and transpeptidation steps of peptidoglycan synthesis, preventing the cross-linking of the bacterial cell wall and leading to cell lysis (Source: StatPearls, 2023).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on D-alanyl-D-alanine terminus of peptidoglycan precursor lipid II (D-Ala-D-Ala).